CategoryCOVID-19

#MSCOVID The Third Jab…The news doesn’t get better for the problem treatments

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.Palomares Cabeza V, Kummer LYL, Wieske L, Hagen RR, Duurland M, Konijn VAL, van Dam KPJ, Stalman EW, van de Sandt CE, Boekel L, Verstegen NJM, Steenhuis M, Rispens T, Tas SW, Wolbink G, Killestein J, Kuijpers TW, van Ham SM, Eftimov F, Brinke AT, van Kempen ZLE;...

MS COVID and B cell biology

I guess we have all had enough of COVID-19, but events have allowed us to uncovermore about biology of the disease modifying treatments. Anti-CD20 B cell depleting antibodies have come under the spotlight in terms of antibody response and B cell repopulation. We made the point years ago that anti-CD20 may be over-dosedand that many people may not require dosing every 6 months (with...

MS COVID19. Can you be the next Omicron

What does this say? In this study immunosuppressed people including those taking B cell depleting therapies, were given an anti-viral therapy following infection with SARS-CoV-2. Most people recovered from their infections, which is what the anti-viral antibody therapy was supposed to do. However afew people did not clear the virus quickly and in these people they found mutations in the surviving...

The third dose #MSCOVID

You have known this for months if you have been reading my posts, but that they replicate what has gone before suggests that it is the correct observation Milo R, Staun-Ram E, Karussis D, Karni A, Hellmann MA, Bar-Haim E, Miller A; Israeli Neuroimmunology Study Group on COVID-19 Vaccination in Multiple Sclerosis. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients...

#MSCOVID-19

This study assessed whether any treatment influences susceptibility and it found none….others have reported influences with CD20-depleting antibodies. So as it is not clear I think that this means the impact is not great. However, these bits of info were generated in the pre-omicron era….the answer to this question should be answerable better in the omicron era and if it is going to...

MSCOVID19

Mariottini A, Bertozzi A, Marchi L, Di Cristinzi M, Mechi C, Barilaro A, Massacesi L, Repice AM. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. J Neurol. 2022. doi: 10.1007/s00415-022-11003-3.  Background: Few data are available so far on the antibody-mediated immune response to anti-SARS-Cov2...

#MSCOVID19

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis.Gyang TV, Evans JP, Miller JS, Alcorn K, Peng J, Bell EH, Zeng C, Gumina R, Liu SL, Segal BM.Mult Scler J Exp Transl Clin. 2022 Mar 22;8(1):20552173221087357. doi: 10.1177/20552173221087357. Background: Patients with multiple sclerosis (pwMS) are often treated with disease modifying...

COVID stopped prescriptions

Williams T, Mishra R, Bharkhada B, Shields A, Dorsey R, Chataway J, Brownlee WJ. Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study. J Neurol Neurosurg Psychiatry. 2022 Mar 10:jnnp-2021-328340. doi: 10.1136/jnnp-2021-328340. The provision of multiple sclerosis (MS) services in England was profoundly impacted by...

#MSCOVID19….Get the Boost

Response to COVID-19 booster vaccinations in seronegative people with MS. Tallantyre, E. C., Scurr, M. J., Vickaryous, N., Richards, A., Anderson, V., Baker, D., Chance, R., Evangelou, N., George, K., Giovannoni, G., Harding, K., Hibbert, A., Ingram, G., Jolles, S., Jones, M., Kang, A., Loveless, S., Moat, S., Robertson, N., Rios, F., Schmierer, K., Willis, M., Godkin, A., Dobson, R. MedRXiv .10...

Vaccinating Fingolimod II

You asked “ Thank you for sharing this article. I have a few questions I hope someone may be able to answer. 1.What does this mean? 2. What is the difference between humoral protection and adaptive cellular immunity? 3. Is it reasonable to apply these results to other SP1 modulators? Is it reasonable to apply these results to other SP1 modulators?. To some extent yes because they all do a...

Translate

Categories

Recent Posts

Recent Comments

Archives